A recent analysis of adverse drug reactions by Indian Pharmacopoeia Commission revealed that combinations of beta-blockers ...

The pharmaceutical industry spends a ton of money on drug ads. This should come as no surprise to anyone who watches TV or ...

New international consensus guidelines were developed through a research method, known as a Delphi process, that used a ...

Children younger than 6 years of age who are prescribed extended-release stimulants for attention-deficit hyperactivity disorder (ADHD) may experience ...

The most effective antipsychotic drug for people with treatment-resistant schizophrenia is clozapine. Yet, across the world, ...

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

To date, almost 400 reports of acute pancreatitis have been received from people using GLP-1 drugs such as Mounjaro, Wegovy, ...

Attention-deficit/hyperactivity disorder (ADHD) medications remain associated with a reduced risk for various real-world ...

Srinagar: In a major step toward enhancing drug safety and patient care, the Sher-e-Kashmir Institute of Medical Sciences ...

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

FDA accelerates approval of sunvozertinib for advanced NSCLC with EGFR mutations, offering new hope for patients after ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...